Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.
2.

Extending a Systems Model of the APP Pathway: Separation of β- and γ-Secretase Sequential Cleavage Steps of APP.

van Maanen EMT, van Steeg TJ, Ahsman MJ, Michener MS, Savage MJ, Kennedy ME, Kleijn HJ, Stone J, Danhof M.

J Pharmacol Exp Ther. 2018 Jun;365(3):507-518. doi: 10.1124/jpet.117.244699. Epub 2018 Mar 21.

PMID:
29563326
3.

Influence of body composition on disposition of the highly fat distributed compound as analysed by physiologically based pharmacokinetic (PBPK) modeling and simulation.

Goto A, Tagawa Y, Moriya Y, Sato S, Yamamoto M, Wakabayashi T, Tsukamoto T, DeJongh J, van Steeg TJ, Moriwaki T, Asahi S.

Biopharm Drug Dispos. 2017 Dec;38(9):543-552. doi: 10.1002/bdd.2106. Epub 2017 Nov 9.

PMID:
28948605
4.

Impact of acute fat mobilisation on the pharmacokinetics of the highly fat distributed compound TAK-357, investigated by physiologically based pharmacokinetic (PBPK) modeling and simulation.

Goto A, Tagawa Y, Moriya Y, Sato S, Furukawa Y, Wakabayashi T, Tsukamoto T, DeJongh J, van Steeg TJ, Moriwaki T, Asahi S.

Biopharm Drug Dispos. 2017 Sep;38(6):373-380. doi: 10.1002/bdd.2075. Epub 2017 May 23.

PMID:
28256717
5.

The application of mathematical modelling to the design of bispecific monoclonal antibodies.

van Steeg TJ, Bergmann KR, Dimasi N, Sachsenmeier KF, Agoram B.

MAbs. 2016;8(3):585-92. doi: 10.1080/19420862.2016.1141160. Epub 2016 Feb 24.

6.

Systems Pharmacology Analysis of the Amyloid Cascade after β-Secretase Inhibition Enables the Identification of an Aβ42 Oligomer Pool.

van Maanen EM, van Steeg TJ, Michener MS, Savage MJ, Kennedy ME, Kleijn HJ, Stone JA, Danhof M.

J Pharmacol Exp Ther. 2016 Apr;357(1):205-16. doi: 10.1124/jpet.115.230565. Epub 2016 Jan 29.

PMID:
26826190
7.

Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice.

Benson N, de Jongh J, Duckworth JD, Jones HM, Pertinez HE, Rawal JK, van Steeg TJ, Van der Graaf PH.

Antimicrob Agents Chemother. 2010 Mar;54(3):1179-85. doi: 10.1128/AAC.00551-09. Epub 2009 Dec 22.

8.

Effect of altered AGP plasma binding on heart rate changes by S(-)-propranolol in rats using mechanism-based estimations of in vivo receptor affinity (K(B,vivo)).

van Steeg TJ, Krekels EH, Freijer J, Danhof M, de Lange EC.

J Pharm Sci. 2010 May;99(5):2511-20. doi: 10.1002/jps.22014.

PMID:
20020526
9.

Influence of plasma protein binding on pharmacodynamics: Estimation of in vivo receptor affinities of beta blockers using a new mechanism-based PK-PD modelling approach.

van Steeg TJ, Boralli VB, Krekels EH, Slijkerman P, Freijer J, Danhof M, de Lange EC.

J Pharm Sci. 2009 Oct;98(10):3816-28. doi: 10.1002/jps.21658.

PMID:
19117045
10.

Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model.

van Steeg TJ, Freijer J, Danhof M, de Lange EC.

J Pharmacol Exp Ther. 2008 Mar;324(3):1234-42. Epub 2007 Dec 27.

PMID:
18162599
11.
12.

Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats.

van Steeg TJ, Krekels EH, Danhof M, de Lange EC.

J Pharmacol Toxicol Methods. 2007 Jul-Aug;56(1):72-8. Epub 2007 Feb 15.

PMID:
17376707
14.

Cutaneous side-effects of transdermal iontophoresis with and without surfactant pretreatment: a single-blinded, randomized controlled trial.

Li GL, Van Steeg TJ, Putter H, Van Der Spek J, Pavel S, Danhof M, Bouwstra JA.

Br J Dermatol. 2005 Aug;153(2):404-12.

PMID:
16086757
15.

Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment.

Li GL, de Vries JJ, van Steeg TJ, van den Bussche H, Maas HJ, Reeuwijk HJ, Danhof M, Bouwstra JA, van Laar T.

J Control Release. 2005 Jan 3;101(1-3):199-208.

PMID:
15588905

Supplemental Content

Loading ...
Support Center